Loading stock data…
RxSight, Inc. (RXST)
$6.13-0.24 (-3.84%)
Market OpenUpdated 11:06 AM EDT
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
RxSight, Inc. in the Healthcare sector is trading at $6.45 with a market capitalization of $265M. Wall Street consensus targets $7.79 (8 analysts), implying a +20.7% move over the next 12 months. The stock is currently 51% below its 52-week high of $13.22, remaining 14.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $30.89M↓ | $32.61M↑ | $30.34M↓ | $33.64M↓ | $37.90M |
| Gross Profit | $23.50M↓ | $25.26M↑ | $24.23M↓ | $25.19M↓ | $28.33M |
| Operating Income | -$17.83M↓ | -$11.34M↑ | -$12.18M↑ | -$14.00M↓ | -$10.67M |
| Net Income | -$15.88M↓ | -$9.15M↑ | -$9.82M↑ | -$11.79M↓ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that ena...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$265.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.83%
Volume
Today's trading volume
133,135
Recent News
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?
Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]
RxSight (RXST) Q2 2026 Earnings Call Transcript
Alcon partnership revenue offsets 19% product sales decline from competitive pressure.
RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ...
RxSight Inc (RXST) navigates a challenging quarter with a 19% product sales drop while securing a transformative $200 million Alcon collaboration and planning to double its U.S. sales team.
RxSight Q2 Earnings Call Highlights
RxSight (NASDAQ:RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the b
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?